BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+0.82%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$22.8B
AUM Growth
+$22.8B
(+0.01%)
Cap. Flow
+$265M
Cap. Flow
% of AUM
1.16%
Top 10 Holdings %
Top 10 Hldgs %
82.65%
Holding
132
New
12
Increased
20
Reduced
6
Closed
10
Top Buys
| 1 |
Ascendis Pharma
ASND
|
$160M |
| 2 |
Pacific Biosciences
PACB
|
$57.3M |
| 3 |
Kodiak Sciences
KOD
|
$52.2M |
| 4 |
Travere Therapeutics
TVTX
|
$44.9M |
| 5 |
BLUE
bluebird bio
BLUE
|
$43.4M |
Top Sells
| 1 |
Apellis Pharmaceuticals
APLS
|
$144M |
| 2 |
ADC Therapeutics
ADCT
|
$34.5M |
| 3 |
AMRN
Amarin Corp
AMRN
|
$23.4M |
| 4 |
Protagonist Therapeutics
PTGX
|
$20.4M |
| 5 |
Aurinia Pharmaceuticals
AUPH
|
$13.3M |
Sector Composition
| 1 | Healthcare | 97.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
| $8.03B | 35.26% | 47,288,259 | – | – |
|
|
ONC
2
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $4.24B | 18.6% | 11,668,897 | – | – |
|
3
Incyte
INCY
$16.5B
| $2.2B | 9.67% | 32,022,125 +393 | +0% | +$27K |
|
|
4
Kodiak Sciences
KOD
$478M
| $1.41B | 6.19% | 14,681,304 +543,423 | +4% | +$52.2M |
|
|
5
Ascendis Pharma
ASND
$11.8B
| $724M | 3.18% | 4,541,604 +1,001,334 | +28% | +$160M |
|
6
Acadia Pharmaceuticals
ACAD
$4.38B
| $696M | 3.06% | 41,910,704 | – | – |
|
7
BioMarin Pharmaceuticals
BMRN
$11.2B
| $589M | 2.59% | 7,620,494 +31,200 | +0.4% | +$2.41M |
|
8
argenx
ARGX
$43.6B
| $338M | 1.48% | 1,119,557 | – | – |
|
9
Prelude Therapeutics
PRLD
$68.5M
| $316M | 1.39% | 10,123,824 | – | – |
|
|
NVTA
10
DELISTED
Invitae Corporation
NVTA
| $281M | 1.23% | 9,873,488 -375,087 | -4% | -$10.7M |
|
|
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $249M | 1.1% | 1,409,784 | – | – |
|
12
AbCellera Biologics
ABCL
$1.25B
| $209M | 0.92% | 10,450,180 | – | – |
|
|
IGMS
13
DELISTED
IGM Biosciences
IGMS
| $208M | 0.91% | 3,156,102 | – | – |
|
14
BioCryst Pharmaceuticals
BCRX
$1.74B
| $183M | 0.8% | 12,710,818 | – | – |
|
15
Kymera Therapeutics
KYMR
$2.95B
| $140M | 0.62% | 2,384,742 +425,531 | +22% | +$25M |
|
|
16
Pacific Biosciences
PACB
$393M
| $139M | 0.61% | 5,444,963 +2,242,991 | +70% | +$57.3M |
|
17
Madrigal Pharmaceuticals
MDGL
$9.76B
| $120M | 0.53% | 1,499,213 | – | – |
|
18
Legend Biotech
LEGN
$6.41B
| $120M | 0.52% | 2,364,003 +699,469 | +42% | +$35.4M |
|
|
AMRN
19
Amarin Corp
AMRN
$311M
| $111M | 0.49% | 21,856,032 -4,597,390 | -17% | -$23.4M |
|
20
Immunocore
IMCR
$1.62B
| $93.4M | 0.41% | 2,520,730 | – | – |
|
21
Heron Therapeutics
HRTX
$207M
| $86.9M | 0.38% | 8,131,678 | – | – |
|
22
Cerus
CERS
$251M
| $83.5M | 0.37% | 13,713,195 | – | – |
|
|
GBT
23
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $82M | 0.36% | 3,217,441 | – | – |
|
|
ALLK
24
DELISTED
Allakos
ALLK
| $74.4M | 0.33% | 703,050 | – | – |
|
25
Nurix Therapeutics
NRIX
$714M
| $73.5M | 0.32% | 2,454,082 | – | – |
|